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Methyl-␤-cyclodextrin: an alternative carrier for
intravenous infusion of palmitate during tracer studies in
swine ž Sus scrofa domestica/ 夽
Diane Wray-CahenU , Thomas J. Caperna, Norman C. Steele
USDA-ARS, Li¨ estock and Poultry Science Institute, Growth Biology Laboratory, Belts¨ ille, MD 20705, USA
Received 18 July 2000; received in revised form 23 April 2001; accepted 25 April 2001

Abstract
Fatty acid-free albumin has been the standard carrier for intravenous infusion of fatty acids to study in vivo lipid
metabolism. However, subjects can have adverse reactions to infusion of albumin. We sought an alternative to albumin
as a carrier for intravenous infusion of fatty acids, using the pig as a model. Cyclodextrins are naturally occurring
water-soluble molecules that can serve as carriers for lipid-soluble compounds. 13 C-palmitate was complexed to either
20% methyl-␤-cyclodextrin, 20% 2-hydroxypropyl-␤-cyclodextrin, or 5% porcine albumin Žisotopic purity of infusates:
99.22" 0.06%.. 13 C-palmitate᎐albumin was infused under fed conditions and 13 C-palmitate᎐methyl-␤-cyclodextrin was
infused under fasted and fed conditions in 50-kg pigs. Palmitate remained in solution at 4⬚C in methyl-␤-cyclodextrin,
but precipitated at 25᎐30⬚C in 2-hydroxypropyl-␤-cyclodextrin. Pigs infused with 13C-palmitate᎐methyl-␤-cyclodextrin
maintained normal body temperature and appetite; those infused with 13 C-palmitate᎐albumin became anorexic and
exhibited other negative side effects to albumin. Palmitate oxidation rates under fed conditions were similar using either
13
C-palmitate᎐methyl-␤-cyclodextrin or 13 C-palmitate᎐albumin complexes. Fasting increased 13C-palmitate᎐methyl-␤cyclodextrin oxidation by approximately eight-fold. These data suggest that methyl-␤-cyclodextrin may be a suitable
substitute for albumin in fatty acid metabolism studies in swine. 䊚 2001 Published by Elsevier Science Inc.
Keywords: Albumin; Fasted; Fatty acid oxidation; Fed; Methyl-␤-cyclodextrin; Palmitate; Swine; Tracer methodology

1. Introduction
Fatty acid-free serum albumin has been the
tracer carrier of choice for lipid metabolism stud夽
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ies ŽWolfe et al., 1980; Wolfe, 1992. and human
albumin has been used in numerous stable isotopic studies, in both humans and dogs, with no
apparent ill effects ŽWolfe, 1992.. However, not
all subjects tolerate high infusion rates of albumin, limiting the amount of stable isotopic
tracer that can be infused. Although negative
reactions to 5% albumin infusions are relatively
rare ŽMcClelland, 1990., albumin infusion can
cause pyrogenic and anaphylactic reactions in humans ŽStafford et al., 1988; Gales and Erstad,
1993; Pool and McLeod, 1995. and in animals
ŽRing et al., 1977.. The safety of the common
practice of infusion of human albumin in the
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Piga

Body
wt. Žkg.

ALB
conc.
Ž%.

FI Žkg.
Before start
of ALB-PA
infusion b

After start
of ALB-PA
infusion c

A

55.1

7e

1.44

0

B

53.7

5e

1.38

0

C

58.4

5e

1.44

0

D
E
F
G

59.4
63.3
54.9
49.6

5e
5f
5f
5g

1.44
1.50
1.44
1.32

0
0
0.72
0.22

a

Adverse
responseŽs. to
of ALB-PA
infusion

Ra
Žmol miny1
kgy1 .

Vomited after
60 and 105 min,
shaking
Vomited after
50 and 135 min,
shaking
Vomited after
50 min
None observed
Listless, shaking
Listless, full FI
Listless,
reduced FI

3.63

PA oxidation
Žmol miny1 kgy1 .

PA
uptake
oxidized
Ž%.

768

0.646

17.8

1.53

1100

0.078

5.1

1.86

630

0.111

6.0

2.17
5.69
3.87
4.41

824
841
NDh
744

0.195
0.554
0.327d
0.136

9.0
9.7
8.4d
3.1

PA

CO2

One additional pig was infused, but is not shown because its catheters shut down when ALB-PA was infused. This pig also stopped eating and had labored breathing.
Feed consumed over 6 h prior to initiation of ALB-PA infusion, including FI during bicarbonate infusion. Animals offered 4.2 g hy1 kgy1 .
c
Feed consumed over 3 h during the ALB-PA infusion. Animals offered 4.2 g hy1 kgy1 .
d
Estimated using R aŽCO 2 . values from other pigs Žnot used in comparison with methyl-␤-cyclodextrin infusion..
e
Essentially fatty acid-free porcine albumin ŽSigma, A9422..
f
Essentially fatty acid-free bovine albumin ŽSigma, A9205..
g
Essentially fatty acid-free, essentially globulin-free porcine albumin ŽSigma, A1173..
h
ND, not determined Žbicarbonate infusion line disconnected..
b
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Table 1
Feed intake ŽFI., palmitate ŽPA. rate of appearance w R a ŽPA.x, CO 2 production rate w R a ŽCO 2 .x and palmitate oxidation for individual animals when albumin ŽALB. was used as a
carrier for 13 C-palmitate tracer in growing pigs

D. Wray-Cahen et al. r Comparati¨ e Biochemistry and Physiology Part A 130 (2001) 55᎐65

management of certain illnesses in patients has
recently been an issue of discussion and controversy ŽMcClelland, 1998; Offringa, 1998.. It has
been suggested that infusion of albumin may increase the relative risk of death in some circumstances ŽCochrane Injuries Group, 1998.. In addition to the possible risk of its use, human albumin
for infusion can be very expensive and its availability has been limited. Infusion-quality albumin
has not been readily available commercially for
all species of animal models. Some researchers
have used autologous serum as a carrier ŽDunshea
et al., 1992., but this may not always be feasible,
especially if it is necessary to infuse a large
amount of tracer. Using a non-blood-derived carrier for infusion of fatty acids in metabolism
studies may reduce the potential risk of albumin
infusion and reduce the cost of the infusate as
well.
In a series of preliminary studies, we infused
several pigs with a variety of fatty acid-free albumin preparations from both porcine and bovine
sources Žsee Table 1.. However, the palmitate᎐albumin mixtures that we infused into growing pigs
consistently caused adverse reactions, including
anorexia, vomiting, and elevated body temperature. In order to avoid these negative reactions,
we sought a non-blood-derived alternative to
serum albumin for use as a fatty acid-tracer carrier in fatty acid oxidation studies.
␤-Cyclodextrins can prevent the precipitation
of non-polar substances in aqueous solutions
ŽMcDonald and Muzumdar, 1998.. Data from in
vitro studies suggested that ␤-cyclodextrins may
have potential as fatty acid-tracer carriers in fatty
acid oxidation studies ŽKato et al., 1993, 1994.,
and unsubstituted or natural ␤-cyclodextrin has
been shown to behave similarly to defatted serum
albumin in in vitro preparations ŽRamadoss et al.,
1976.. Intravenously infused substituted ␤-cyclodextrins have also been used as carriers for a
wide variety of non-water-soluble substances in
humans ŽIrie et al., 1992; Vandewoude et al.,
1997., rabbits ŽIrie et al., 1992., rats ŽPackard and
Teather, 1997. and dogs ŽLoscher et al., 1995..
The parent compound, ␤-cyclodextrin, is a cyclic
oligosaccharide consisting of seven glucopyranose
units with a hydrophobic interior. Water solubility
of natural ␤-cyclodextrin is poor Ž1.8 g per 100
ml., but chemical substitutions Že.g. methyl and
hydroxypropyl groups. can increase the solubility
many fold Ž) 50 g per 100 ml.. The objective of
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the present study was to determine the feasibility
of using ␤-cyclodextrins as non-blood-derived carriers for palmitate in fatty acid oxidation studies
in growing pigs.

2. Materials and methods
2.1. Animals
We used unanesthetized crossbred female pigs
wŽ Sus scrofa domestica. 52 " 3 kg, from the
Beltsville Agricultural Research Center ŽBARC.
swine herdx to demonstrate the feasibility of using
methyl-␤-cyclodextrin as a substitute for albumin
as a carrier for 13 C-palmitate in in vivo infusion
studies. All animal care and use procedures were
approved by the BARC Institute Animal Care
and Use Committee. Pigs were restrictively fed a
corn᎐soybean meal based diet at 80% estimated
ad libitum intake based on individual body weight
Ždiet: 18% crude protein, 3.14 Mcal kgy1 ., and
were housed in metabolism crates for at least 1
week before study. Before being placed in crates,
pigs were trained to breathe into a breath collection mask.
Catheters were non-surgically placed in the
jugular veins Žvia both medial auricular veins.
under general anesthesia w2 mg kgy1 each of
xylazine and Telazol ŽFort Dodge Laboratories
Inc., Fort Dodge, IA.x to allow for simultaneous
sampling and infusion ŽWray-Cahen et al., 1993..
Measurements were taken at least 4 days after
catheterization. Kinetic measurements were carried out under steady-state fed or fasted conditions.
In preliminary studies, eight pigs were infused
with 13 C-palmitate᎐albumin complexes. The adverse responses to the albumin infusion are shown
in Table 1. The initiation of the 13 C-palmitate᎐
albumin infusion appeared to cause three pigs to
vomit within 1 h and to cause the catheters of one
pig to lose patency. Only two pigs infused with
the 13 C-palmitate᎐albumin complex continued to
consume feed throughout the infusion period Žone
at a reduced intake.. Two other pigs stopped
eating, but did not vomit. Three pigs Ž57.4" 4.1
kg. were used as a comparison for the four pigs
Ž50.5 " 0.9 kg. infused with the 13 C-palmitate᎐methyl-␤-cyclodextrin complex. Each pig
given the 13 C-palmitate᎐methyl-␤-cyclodextrin
complex was infused under both fed and fasted
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conditions, on two separate, non-consecutive days.
The pigs receiving the 1 3 C-palm itate ᎐
albumin complex were infused only under fed
conditions. Under fed conditions, pigs received
one-tenth of their daily ration, hourly, beginning
2 h before basal samples were collected and continuing throughout the collection period, so that
the entire ration was consumed over a 9-h period.
Under fasted conditions, collections began following an 18-h fast. Feed refusals were recorded.
Rectal body temperatures were recorded during
two of the infusions for each infusate.
2.2. Infusate preparation
w1- 13 Cx-Palmitate Žpotassium salt; 99AP. was
obtained from Mass Trace Inc. ŽWoburn, MA.. In
the present investigation, w1- 13 Cx-palmitate was
bound to one of three potential carriers: Ži. essentially fatty acid-free albumin ŽSigma Chemical
Co., St. Louis, MO: bovine, A9205; porcine, A9422; and porcine essentially globulin-free, A1173;
see Table 1 for details.; Žii. methyl-␤-cyclodextrin
ŽAldrich Chemical Co. Inc., Milwaukee, WI;
33,261-5.; and Žiii. 2-hydroxypropyl-␤-cyclodextrin
ŽAldrich Chemical Co. Inc.; 33,260-7.. The w113 x
C -palmitate Žpotassium salt. was dissolved in
pyrogen-free deionized H 2 O and then added to a
5% wrv albumin solution Ž5 g albumin per 100 ml
sterile physiological saline. as described by Wolfe
Ž1992. using 3 g of w1- 13 Cx-palmitate per 100 g
essentially fatty acid-free albumin. The solution
was prepared at 60⬚C, filtered through a 0.2-m
sterile filter into a sterile bottle and stored at
room temperature until used the following day.
The w1- 13 Cx-palmitate Žpotassium salt. ᎐cyclodextrin complexes were prepared as follows.
Methyl-␤-cyclodextrin or 2-hydroxypropyl-␤cyclodextrin was dissolved in sterile phosphatebuffered saline ŽPBS, GIBCO-BRL, Life Technologies, Grand Island, NY; 14190-151. at
50᎐60⬚C at 20 g of ␤-cyclodextrin per 100 ml PBS
Ž20% wrv.. The w1- 13 Cx-palmitate Žpotassium salt.
was directly dissolved in one of the 20% cyclodextrin solutions at 3 g of palmitate per 100 g ␤cyclodextrin. The mixtures were prepared at
50᎐60⬚C and filtered through a 0.2-m sterile
filter into a sterile bottle and stored at 4⬚C until
infused. The w1- 13 Cx-palmitate᎐methyl-␤-cyclodextrin mixture was reheated to approximately
30⬚C, if necessary, to clarify the solution before
infusion. The hydroxypropyl-␤-cyclodextrin mix-

ture was not used in infusion studies for reasons
described below. The final infusate enrichments
Ž99.22 " 0.06%. and palmitate concentrations
were determined by gas chromatography-mass
spectrometry ŽMetabolic Solutions Inc.; Merrimack, NH.. The final palmitate concentration after filtering of both the 5% albumin and the
methyl-␤-cyclodextrin infusate preparations was
75.2" 1.8% of the calculated values. During the
preparation of the 7% albumin infusate, a greater
proportion of the palmitate was lost, and the final
palmitate concentration was 66.7% of the calculated amount. Values used in the palmitate oxidation calculations were those determined by mass
spectrometry analysis.
2.3. Stability of palmitate᎐ ␤-cyclodextrin complexes
As with the palmitate᎐albumin mixture, the
palmitate ᎐methyl-␤-cyclodextrin mixture remained in solution when it was cooled to room
temperature. Unlike the palmitate-albumin mixture, it also remained in solution when stored at
4⬚C for more than 2 weeks. When the
palmitate᎐methyl-␤-cyclodextrin mixture was
stored for periods of over 1 month, the palmitate
began to precipitate, but it quickly resolubilized
when heated to approximately 30⬚C. Upon
cooling, the palmitate᎐methyl-␤-cyclodextrin remained in solution. The palmitate solubilized in
2-hydroxypropyl-␤-cyclodextrin precipitated out of
solution when cooled to 25᎐30⬚C. It could be
resolubilized with heating, but would only remain
in solution if kept warm. Therefore, we determined that the 2-hydroxypropyl-␤-cyclodextrin
complex was not suitable for the in vivo infusion
studies.
2.4. Infusion protocol
A 90-min primed-continuous Ž0.6 or 1.2 mmol
kgy1 hy1 , fed or fasted conditions, respectively.
infusion of NaH 13 CO 3 ŽMass Trace Inc.. was
used to prime the CO 2rbicarbonate pool Žas described by Wolfe, 1992. and to determine basal
CO 2 production. Immediately following the
NaH 13 CO 3 infusion, w1- 13 Cx-palmitate solutions
were infused at a constant rate Ž0.068 mol 13 Cpalmitate miny1 kgy1 . for 4 h. The w1- 13 Cxpalmitate-albumin mixture was administered at a
rate of 0.89 ml hy1 kgy1 to achieve the target
tracer infusion rate. Because the w1- 13 Cx-palmi-
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tate-methyl-␤-cyclodextrin mixture was four-fold
more concentrated than the albumin complex, the
solution was infused at one-fourth the volume
hy1 kgy1 . Breath and blood samples were collected during a basal, pre-infusion period, and
when isotopic enrichment plateau was achieved
Ž60᎐90 min for bicarbonate infusion and 120᎐180
min for palmitate infusion.. Additional samples
were collected to ensure that a plateau had been
achieved Žbicarbonate: t 30, 45, 60, 70, 80 and 90
min; palmitate: t 30, 60, 90, 120, 135, 150, 165 and
180 min., but these were not included in the
calculations. One animal was infused with the
palmitate᎐methyl-␤-cyclodextrin mixture for 360
min with samples taken every 30 min for further
verification that the plateau was achieved before
the 120᎐180-min window. Samples Žbreath andror
heparinized blood. were injected into evacuated
vials for measurement of 13 CO 2 enrichments.
Blood samples were collected into heparinized
syringes and plasma was harvested after centrifugation for measurement of plasma enrichments of
w1- 13 Cx-palmitate. Breath and plasma enrichments
were determined by mass spectrometry ŽMetabolic Solutions Inc., Merrimack, NH..
2.5. Mass spectrometry analysis
w1- 13 Cx-Palmitate enrichment in plasma and infusate was determined by gas chromatographymass spectrometry ŽGCMS. on a Hewlett Packard
5989A system ŽPalo Alto, CA. using a Restek
Rtx-1 capillary column. Extracted fatty acids were
derivatized with addition of MTBSTFAr
acetonitrile Ž1:1 vrv. to produce a t-BDMS
derivative. Quantification of the natural and w113 x
C -palmitate fatty acid derivatives was carried
out by GCMS in the electron impact mode. 13 CO 2
enrichment in breath and heparinized whole blood
samples was determined by gas isotope ratio mass
spectrometry ŽIRMS. on a Europa Scientific
ŽCrewe, UK. 20r20 stable isotope analyzer. The
breath samples were loaded directly on the IRMS
via a Europa Scientific ABCA sample purification
system. Blood samples were first acidified with a
saturated citric acid solution to liberate the carbon dioxide and the released gas loaded on the
IRMS in the same manner as the breath samples.
2.6. Calculations and statistics
The palmitate entry rate w R aŽpalmitate.x, the
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CO 2 production rate w R aŽCO 2 .x during the bicarbonate infusion, the palmitate oxidation rate, and
the percent of palmitate uptake oxidized were
calculated as follows ŽWolfe, 1992.:
R a Ž palmitate . s Ž Ž EiprEpalm . y 1 . ) Fpalm
R a Ž CO 2 . s Ž Ž EibrEbCO 2 . y 1 . ) Fbicarb
Palmitate oxidation
s Ž EpCO 2 ) R a Ž CO 2 . . rEpalm
Palmitate uptake oxidized
Ž%. s

pCO 2 ) R a

žŽ E

Ž CO 2 . . rFpalm

/ )100

where Eip is the isotope enrichment of the 13 Cpalmitate infusate, Epalm is the plateau enrichment of plasma palmitate, Fpalm is the infusion
rate of the 13 C-palmitate infusate, Eib is the isotope enrichment of the 13 C-bicarbonate infusate,
E bCO 2 is the plateau enrichment of plasma or
breath CO 2 during the 13 C-bicarbonate infusion,
Fbicarb is the infusion rate of the 13 C-bicarbonate
infusate, and EpCO 2 is the plateau enrichment of
plasma or breath CO 2 during the 13 C-palmitate
infusion.
The primary comparisons of interest were Ži.
between fed pigs receiving either the albumin or
the methyl-␤-cyclodextrin complex in order to
evaluate whether the results were similar for the
two methods and Žii. between fed and fasted
states in pigs receiving the methyl-␤-cyclodextrin
complex to determine if this method could detect
changes in palmitate oxidation. To compare data
from fed pigs infused with the albumin vs. the
methyl-␤-cyclodextrin complex, ANOVA was
used. For this comparison, the level of significance was set at P- 0.1 and the degrees of
freedom within samples set at 4, to reduce likelihood of a type II error, concluding that there is
no difference between infusion methods, when a
difference does exist. For the fed and fasted states
of pigs receiving the methyl-␤-cyclodextrin complex infusion Žeach pig studied under both fed
and fasted conditions., the average plateau values
were compared using paired t-tests and the level
of significance was set at P- 0.05. Data in tables
are expressed as mean " standard error of the
mean ŽS.E.M...
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3. Results
3.1. Albumin infusion
In an initial infusion with a higher concentration of porcine albumin Ž7%., the pig vomited
within 60 min of initiation of the palmitate᎐
albumin complex infusion ŽPig A, see Table 1.;
rectal temperature was unchanged at T30 min,
elevated by q0.5⬚C at T60 min, q1.0⬚C at T90
min, and q1.5⬚C at T120 ᎐ 180 min. Frequent temperatures were also taken in a second pig infused
with a 5% albumin complex. It also had elevated
rectal temperature within 60 min of the initiation
of infusion of the complex. Pigs had normal rectal
body temperatures the day following the infusion.
Seven similar pigs received infusions of palmitate
complexed with 5% albumin. One of these pigs
was severely affected by the palmitate᎐albumin
complex infusion and displayed symptoms of anaphylaxis. The pig was distressed, suffered from
extremely labored breathing and exhibited diffuse
erythema or flushing of the skin. The catheters of
this pig also lost patency shortly after the initiation of the albumin infusion, and therefore no
palmitate data were available from this animal.
Albumin without palmitate bound to it was also
infused into one pig and similar adverse responses were observed.
The palmitate oxidation data obtained from the
pigs infused with palmitate᎐albumin complexes
are presented in Table 1. Most of these pigs
reacted negatively to infusion of albumin Ži.e.
vomiting, shaking, fever, andror rapid breathing..
Pigs infused with the palmitate᎐albumin com-

plexes had reduced feed intakes Žan average reduction of 28% for total daily intake.. Most lost
interest in feed within 1 h after initiation of
palmitate᎐albumin complex infusion and, on average, consumed less than 20% of the feed offered during this infusion. The variation in feed
consumed, as well as the other symptoms,
probably contributed to the variation in the individual values for palmitate oxidation. The appetites of all pigs returned by the day following
the infusion. Four pigs did not vomit and two pigs
infused with the w1- 13 Cx-palmitate᎐albumin mixture continued to consume their diet throughout
the infusion period; albeit one at a reduced level.
Summarized oxidation data using the palmitate᎐
albumin complex for three pigs is presented in
Table 2 for a comparison with the pigs receiving
the methyl-␤-cyclodextrin complex.
3.2. Methyl-␤-cyclodextrin infusion
Pigs infused with the w1- 13 Cx-palmitate᎐methyl␤-cyclodextrin mixture showed none of the adverse side effects observed with albumin infusion.
Rectal body temperature was unchanged during
palmitate᎐methyl-␤-cyclodextrin complex infusion. All pigs infused with this complex continued
to consume meals fed hourly during the infusion
and no loss of appetite was observed following
the infusion. The effects of fasting as measured in
pigs infused with the w1- 13 Cx-palmitate᎐methyl␤-cyclodextrin mixture are shown in Table 2. In
the animals infused with the w1- 13 Cx-palmitate᎐
methyl-␤-cyclodextrin complex, fasting increased
palmitate entry rate 1.8-fold Ž P- 0.05. and the

Table 2
Comparison of albumin and methyl-␤-cyclodextrin as carrier for palmitate for the measurement of palmitate entry rate w R aŽpalmitate.x
and oxidation1
Albumin2
Ž n s 3.

Methyl-␤-cyclodextrin
Ž n s 4.

Fed

RaŽpalmitate., mol miny1 kgy1
RaŽCO2 ., mol miny1 kgy1
Palmitate oxidation,
mol miny1 kgy1
% Palmitate uptake oxidized
1

Fed

Fasted

Mean

S.E.M.

Mean

S.E.M.

Mean

S.E.M.

4.09a
803a
0.30a

1.03
30
0.13

1.35bA
1008aA
0.17aA

0.27
87
0.02

2.46B
627B
1.44B

0.61
22
0.36

7.3a

2.1

13.2aA

2.0

58.4B

1.9

Values with different superscripts within the same row are different Žfor fed albumin vs. fed methyl-␤-cyclodextrin, lower case
letters are used: P- 0.1; for methyl-␤-cyclodextrin fed vs. fasted, upper case letters are used: P- 0.05..
2
Means of pigs D, E, and G Žsee Table 1. are presented.
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percentage of palmitate uptake oxidized by
greater than eight-fold Ž P- 0.001.. Fasting also
increased palmitate oxidation Ž P- 0.05..
3.3. Comparison of palmitate oxidation
A comparison of palmitate oxidation measurements made in pigs infused with the w1- 13 Cxpalmitate᎐methyl-␤-cyclodextrin mixture and pigs
infused with the w1- 13 Cx-palmitate᎐albumin mixture is shown in Table 2. Palmitate oxidation
values obtained under fed conditions when w113 x
C -palmitate᎐methyl-␤-cyclodextrin complex
was infused were similar to those obtained using
albumin as a carrier; however, the coefficient of
variation was 1.7᎐3-fold lower with the methyl-␤cyclodextrin mixture. The similarity of plasma
13
C-palmitate and breath 13 CO 2 enrichments
Žabove baseline . for representative pigs using
either albumin or methyl-␤-cyclodextrin as carriers are shown in Fig. 1.

4. Discussion
In the present study, we developed and validated a new technique using methyl-␤-cyclodextrin as a carrier Žrather than fatty acid-free
albumin. for palmitate in vivo infusion studies in
growing pigs. In this study, the fed and fasted
states were used as metabolic tools to elicit known
states of low and high fatty acid oxidation to
determine if the technique could measure these
relatively extreme differences. With fasting, fatty
acid oxidation should increase in the pig ŽCunningham, 1967..
Fatty acid-free albumin has been the standard
fatty acid-carrier used in most metabolic studies
ŽWolfe, 1992.. However, in this study, the pigs
infused with palmitate᎐albumin complexes Žprepared using several sources of porcine and bovine
fatty acid-free albumin. displayed a variety of
adverse reactions. In addition, the experimental
variation in the palmitate oxidation values was
higher in the animals infused with albumin-bound
palmitate. The palmitate oxidation values for the
pigs receiving the palmitate᎐albumin mixture,
while high for a fed animal, were lower than
those observed in the fasted animals receiving the
palmitate᎐methyl-␤-cyclodextrin mixture. The
pigs infused with the palmitate᎐albumin complex
consumed two-thirds of their total diet before the

Fig. 1. Comparison of Ža. plasma isotopic enrichment of w1Cx-palmitate Žexpressed as mol.% excess, MPE, above baseline. and Žb. breath isotopic enrichment of 13 CO 2 Žexpressed
as at.% excess, APE, above baseline . from fed pigs during
infusions of either the w1- 13 Cx-palmitate-methyl-␤-cyclodextrin
mixture Žsolid circles; n s 4. or the w1- 13 Cx-palmitate-albumin
mixture Žopen circles; n s 3.. Error bars represent S.E.M.
13

initiation of the palmitate᎐albumin complex infusion, and although some regurgitated an unmeasured portion of the previously consumed diet,
they were not ‘fasted’. Metabolically, some of the
pigs infused with the palmitate᎐albumin complex
were probably somewhere between the fed and
fasted states. The elevated R aŽpalmitate. value
may have been due to the reduced feed intake in
combination with the elimination of digesta from
the stomach via the albumin-induced vomiting.
The percent of the R aŽpalmitate. which was oxidized in the pigs infused with the palmitate᎐albumin mixture was similar to the values observed
in fed pigs infused with the palmitate᎐methyl-␤cyclodextrin mixture.
The palmitate oxidation rates and the percent
of palmitate uptake oxidized in fed pigs obtained
when methyl-␤-cyclodextrin was used as a carrier
for palmitate were not different to when albumin
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was used as a carrier. The R aŽpalmitate. values
for fasted pigs were higher than the fed pigs
infused with the palmitate᎐methyl-␤-cyclodextrin
mixture, demonstrating that the methyl-␤-cyclodextrin method can detect expected differences in
fatty acid oxidation. This was further supported
by comparison with fasted and fed values in the
literature. In pigs where methyl-␤-cyclodextrin
was used as a carrier, the palmitate oxidation
increased 5᎐12-fold when the pigs were fasted as
compared to oxidation rates observed in the fedstate. This was a similar percentage increase to
that which was observed by Cunningham Ž1967. in
fed and fasted pigs Ž65 kg. using radioisotopic
techniques with infusion of 14 C-palmitate bound
to ox albumin.
We did not determine the associationrdisassociation properties of palmitate᎐methyl-␤cyclodextrin. However, in in vitro studies, ␤cyclodextrin behaved similarly to defatted serum
albumin ŽRamadoss et al., 1976., and methylated
␤-cyclodextrin did not inhibit palmitate oxidation
or impede palmitate bioavailability in vitro for
Mycobacterium leprae ŽIshaque, 1992.. Our data
suggested that this is true for in vivo studies as
well.
Other studies using the pig model ŽCunningham, 1967; Boyd et al., 1982; Dunshea et al.,
1992. have utilized bovine or porcine albumin or
autologous serum as a carrier for 14 C-fatty acids
without negative side effects. However, relatively
small amounts of radioactive tracers Žas used in
those 14 C studies. need to be infused to measure
metabolite fluxes as compared to stable isotopic
tracers, and therefore studies using radioactive
fatty acid tracers require less total albumin to be
infused. For example in the present study, we
infused albumin at 39 mg kgy1 hy1 , and in a
study using pigs of a similar weight, approximately
6 mg kgy1 hy1 of albumin was infused when a
radioisotope was used ŽDunshea et al., 1992., a
difference greater than six-fold.
We did not determine the exact cause of the
adverse reactions to albumin infusion, but the
symptoms observed were consistent with anaphylaxis. Previous experience has shown that pigs are
very sensitive to pyrogens and endotoxins in intravenous solutions and feed contaminants that do
not appear to adversely affect some other species
ŽWray-Cahen, unpublished data.. Use of essentially ␥-globulin-free and low endotoxin preparations of bovine albumin reduced, but did not

eliminate, the adverse reactions, nor did their use
prevent the suppression of food intake. We were
unable to obtain the fatty acid-free albumin routinely used in human studies to provide a direct
comparison, but it is possible that pigs would
experience heterologous anaphylaxis with albumin of human origin as well, irrespective of the
purity. A porcine albumin comparable to that
used in human studies was not commercially
available. While severe adverse reactions to human serum albumin infusion in man are relatively
rare, intolerance to infusion of human albumin,
including pyrogenic and anaphylactic reactions
ŽRing et al., 1979; Stafford et al., 1988; Leach,
1991; Pool and McLeod, 1995., and possibly an
increased risk of mortality ŽCochrane Injuries
Group, 1998., have been reported.
We did not observe any adverse side effects
while using methyl-␤-cyclodextrin as a nonblood-derived alternative to serum albumin as a
carrier for w1- 13 Cx-palmitate. This could be due, in
part, to the lower volume of methyl-␤-cyclodextrin compared to albumin infused. However,
this was not likely, because: Ži. we infused one
animal Ždata not shown. at a higher infusion rate
Žusing 10% methyl-␤-cyclodextrin. and observed
no adverse reactions; and Žii. we have observed
no adverse reactions in pigs receiving much higher
infusion rates of other compounds Že.g. infusion
of glucose during hyperinsulinemic᎐euglycemic
clamps.. Use of ␤-cyclodextrins may allow for a
higher infusion rate of a fatty acid tracer than
possible when albumin is used as a carrier. Cyclodextrins have some additional potential advantages over albumin. For example, methyl-␤cyclodextrin is more readily available than infusion-quality albumin and is more cost-effective.
Cyclodextrins have potentially much less batchto-batch variation and are free of contaminating
biological substances, such as residual fatty acids
and immunoglobulins. Refrigeration of the palmitate᎐albumin mixture can also lead to the formation of compounds that are pyrogenic in nature
for humans ŽWolfe 1992.; this did not appear to
be a problem with methyl-␤-cyclodextrin.
Interest in cyclodextrins has been increasing,
both for their use in drug delivery and formulation ŽRajewski and Stella, 1997; Stella and Rajewski, 1997; Thompson, 1997. and for their potential
as a lipid carrier in parenteral nutrition ŽBrewster
et al., 1989; Ohtani et al., 1989; Irie et al., 1992;
Thompson, 1997.. Although infusion of unsubsti-
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tuted ␤-cyclodextrin is unsafe due to its nephrotoxicity ŽStella and Rajewski 1997., modified cyclodextrins vary with regard to this trait of their
parent compound. Irie et al. Ž1992. infused hydroxypropyl ␤-cyclodextrin parenterally into humans without irritation. They also infused hydroxypropyl ␤-cyclodextrin parenterally into rabbits
with no observed morphological changes in most
organs Žincluding liver.. However, very high infusion rates of hydroxypropyl-␤-cyclodextrin did result in some morphological changes in the kidneys, similar to those observed with large i.v.
doses of glucose, sucrose, mannitol, or dextran
ŽIrie et al., 1992.. This may be associated with its
route of clearance. Clearance of i.v.-administered
hydroxypropyl-␤-cyclodextrin, dimethyl-␤-cyclodextrin, and ␤-cyclodextrin appears to be primarily via glomerular filtration, with approximately
90% of infused cyclodextrin appearing in the urine
within less than 24 h ŽFrijlink et al., 1990; Pitha et
al., 1994; Kubota et al., 1996; McCormack and
Gregoriadis, 1996; Thompson, 1997.. Grosse et al.
Ž1999. reported the pharmacokinetics of methyl␤-cyclodextrin in rabbits. They reported a distribution time of approximately 30 min and a
half-life of 7 h. Appearance in urine was not
determined in that study, but methyl-␤-cyclodextrin levels in the kidney were high within 4 h.
It seems highly probable that methyl-␤-cyclodextrin administered i.v. is also cleared by the
kidneys.
The ability to tolerate oral or i.v. dosing of
cyclodextrins appears to vary with species. Cats
have demonstrated adverse reactions to high infusion rates of methyl-␤-cyclodextrin Žpersonal
communication, Dr S.A. Center, Cornell University. and dogs appear to tolerate long-term dietary inclusion of ␤-cyclodextrin better than rats
ŽThompson, 1997.. Methylated ␤-cyclodextrins
with a high degree of substitution Ždi-methyl and
tri-methyl ␤-cyclodextrin. have been found to have
toxic effects when given parenterally, but both
rabbits and mice have been infused with high
doses of methyl-␤-cyclodextrin without exhibiting
any toxic effects ŽGrosse et al., 1999.. The safety
of i.v. administration of methyl-␤-cyclodextrin has
not been fully explored.
Although it was not measured in this study,
there is the potential for methyl-␤-cyclodextrin to
bind or complex with other lipophilic compounds
in the circulation. There is evidence that cyclodextrins have the capacity to bind to and re-
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move cholesterol, vitamin A, bile salts, triglycerides and potentially other lipophilic compounds
from the blood ŽFerezou et al., 1997; Rajewski
and Stella, 1997; Thompson, 1997.. In pigs, 5 and
10% ␤-cyclodextrin diets reduced levels of cholesterol in blood and liver when a high cholesterol
diet was fed ŽFerezou et al., 1997.. Addition of
␤-cyclodextrin to diets also reduced cholesterol
levels in rats and dogs ŽRajewski and Stella, 1997..
It is possible that infused cyclodextrins may bind
to other lipophilic compounds as well. The physiological result of ␤-cyclodextrin binding to
lipophilic compounds may not be predictable ᎏ
in vitro studies suggested that ␤-cyclodextrins may
make some compounds more available to cells
ŽChristian et al., 1999. and the cholesterol-lowering effect of oral ␤-cyclodextrin has not been
consistent in different species ŽThompson, 1997..
In conclusion, we have demonstrated the feasibility of using methyl-␤-cyclodextrin as a substitute for albumin as a carrier for 13 C-palmitate in
in vivo infusion studies to determine the rate of
turnover and oxidation of plasma palmitate in
pigs. The 13 C-palmitate᎐methyl-␤-cyclodextrin
complex was stable at room temperature and the
palmitate tracer complexed with methyl-␤-cyclodextrin has been demonstrated to be available in
vivo. Methyl-␤-cyclodextrin did not have the negative side effects that we have observed with
albumin infusion into pigs. Therefore, it may be a
promising non-blood-derived alternative to serum
albumin for use as a fatty acid-tracer carrier in
fatty acid oxidation studies in growing pigs.
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